Financial terms of the deal were not disclosed. ERS Genomics was formed to provide broad access to CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, PhD.

Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents, and genetically modified cell lines and organisms, ERS Genomics said.

Sherlock launches nonprofit to promote equity, STEM during COVID-19
Sherlock Biosciences has formed the 221b Foundation, a nonprofit organization committed to assisting in the eradication of COVID-19, while supporting...

Making CRISPR safer with new enzyme-based prediction tool
A new technique will help scientists choose the best available gene editing option for any given indication, making CRISPR technology safer, cheaper,...

New gene therapy destroys latent oral herpes in mice
Researchers recently reported that they were able to eliminate latent herpes simplex virus 1 in mice using a new gene editing technique that targets the...